Vera Therapeutics

News

Otsuka joins IgAN market with Voyxact approval in US

Otsuka has claimed FDA approval for its IgAN therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch.

News

Otsuka, Vera stake their claims to IgAN treatment

Otsuka and Vera both have new phase 3 data on drugs for kidney disease IgA nephropathy, but can they make a mark in an increasingly crowded market?

News

Vera prices $250m offer, and other biotech financings

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (I

Otsuka joins IgAN market with Voyxact approval in US

Otsuka, Vera stake their claims to IgAN treatment

Vera prices $250m offer, and other biotech financings

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks